Marc E Mooney1, David V Herin2, Sheila Specker2, David Babb2, Frances R Levin3, John Grabowski2. 1. Department of Psychiatry, University of Minnesota, Minneapolis, United States. Electronic address: moon0078@umn.edu. 2. Department of Psychiatry, University of Minnesota, Minneapolis, United States. 3. New York State Psychiatric Institute & Department of Psychiatry, Columbia University, United States.
Abstract
BACKGROUND:Amphetamine analogs have been demonstrated to have some efficacy in reducing use in cocaine dependent individuals. However, these agents also have potential for abuse. Lisdexamfetamine (LDX), a lysine+dextroamphetamine formulation, has been approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and as a prodrug, has less abuse potential. OBJECTIVE: This pilot study sought to evaluate the safety, tolerability, and efficacy of LDX as a candidate treatment for cocaine dependence. METHODS: A randomized, double-blind, placebo-controlled parallel group study served to evaluate LDX in 43 cocaine-dependent individuals: (1) placebo (PBO; 0mg, n=21), (2) LDX (70mg, n=22). Participants received medication for 14 weeks. Cocaine use was determined based on urine analysis for benzoylecgonine (BE; a cocaine metabolite). RESULTS:Retention rates were higher though not significantly different in the PBO (71.4%) than the LDX condition (57.1%). Compared to those in the PBO condition, those receiving LDX were more likely to report experiencing (ps<0.05) diarrhea (45.5% vs. 14.3%), headaches (45.5% vs. 9.5%), and anxiety (31.8% vs. 4.8%). No differences in medication conditions were observed for blood pressure, heart rate, or body weight. In the randomized sample, no differences in cocaine use were seen. Those receiving LDX reported significantly less craving for cocaine than participants receiving PBO. CONCLUSIONS:LDX did not significantly reduce cocaine use compared to PBO in the randomized sample.
RCT Entities:
BACKGROUND:Amphetamine analogs have been demonstrated to have some efficacy in reducing use in cocaine dependent individuals. However, these agents also have potential for abuse. Lisdexamfetamine (LDX), a lysine+dextroamphetamine formulation, has been approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and as a prodrug, has less abuse potential. OBJECTIVE: This pilot study sought to evaluate the safety, tolerability, and efficacy of LDX as a candidate treatment for cocaine dependence. METHODS: A randomized, double-blind, placebo-controlled parallel group study served to evaluate LDX in 43 cocaine-dependent individuals: (1) placebo (PBO; 0mg, n=21), (2) LDX (70mg, n=22). Participants received medication for 14 weeks. Cocaine use was determined based on urine analysis for benzoylecgonine (BE; a cocaine metabolite). RESULTS: Retention rates were higher though not significantly different in the PBO (71.4%) than the LDX condition (57.1%). Compared to those in the PBO condition, those receiving LDX were more likely to report experiencing (ps<0.05) diarrhea (45.5% vs. 14.3%), headaches (45.5% vs. 9.5%), and anxiety (31.8% vs. 4.8%). No differences in medication conditions were observed for blood pressure, heart rate, or body weight. In the randomized sample, no differences in cocaine use were seen. Those receiving LDX reported significantly less craving for cocaine than participants receiving PBO. CONCLUSIONS:LDX did not significantly reduce cocaine use compared to PBO in the randomized sample.
Authors: S Minozzi; L Amato; M Davoli; M Farrell; A A R L Lima Reisser; P P Pani; M Silva de Lima; B Soares; S Vecchi Journal: Cochrane Database Syst Rev Date: 2008-04-16
Authors: Kathleen M Carroll; Lisa R Fenton; Samuel A Ball; Charla Nich; Tami L Frankforter; Julia Shi; Bruce J Rounsaville Journal: Arch Gen Psychiatry Date: 2004-03
Authors: John J Mariani; Martina Pavlicova; Adam Bisaga; Edward V Nunes; Daniel J Brooks; Frances R Levin Journal: Biol Psychiatry Date: 2012-07-12 Impact factor: 13.382
Authors: John Grabowski; Howard Rhoades; Angela Stotts; Katherine Cowan; Charles Kopecky; Anne Dougherty; F Gerard Moeller; Sohela Hassan; Joy Schmitz Journal: Neuropsychopharmacology Date: 2004-05 Impact factor: 7.853
Authors: M T Bardo; E D Denehy; L R Hammerslag; L P Dwoskin; B E Blough; A Landavazo; J Bergman; S J Kohut Journal: Psychopharmacology (Berl) Date: 2019-07-26 Impact factor: 4.530
Authors: Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum Journal: Exp Clin Psychopharmacol Date: 2016-10 Impact factor: 3.157
Authors: Amy R Johnson; Matthew L Banks; Bruce E Blough; Joshua A Lile; Katherine L Nicholson; S Stevens Negus Journal: Drug Alcohol Depend Date: 2016-05-28 Impact factor: 4.492
Authors: Joshua A Lile; William W Stoops; Craig R Rush; S Stevens Negus; Paul E A Glaser; Kevin W Hatton; Lon R Hays Journal: Drug Alcohol Depend Date: 2016-05-28 Impact factor: 4.492